Replimune Group, Inc. (REPL): Shareholders' Equity
$166.16M
As of 2026-03-31
$105.64M
As of 2026-06-30
-33.1%
3-year compound annual growth
-19.7%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $166.16M | -60.0% | 2026-06-29, Balance as of period end |
| 2025-03-31 | $415.84M | +11.0% | 2026-06-29, Balance as of period end |
| 2024-03-31 | $374.51M | -32.6% | 2025-05-22, Balance as of period end |
| 2023-03-31 | $555.29M | +35.0% | 2024-05-16, Balance as of period end |
| 2022-03-31 | $411.23M | -17.5% | 2023-05-18, Balance as of period end |
| 2021-03-31 | $498.73M | +171.5% | 2022-05-19, Balance as of period end |
| 2020-03-31 | $183.72M | +33.3% | 2021-05-20, Balance as of period end |
| 2019-03-31 | $137.86M | n/m | 2020-06-03, Balance as of period end |
| 2018-03-31 | -$28.07M | n/m | 2020-06-03, Balance as of period end |
| 2017-03-31 | -$11.52M | n/a | 2019-06-28, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Replimune Group, Inc. (REPL) | 2026-03-31 | $166.16M | -60.0% |
| Prokidney Corp. (PROK) | 2025-12-31 | -$1.01B | n/m |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $120.87M | -21.1% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $246.94M | +245.2% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $207.18M | -35.0% |
| Kodiak Sciences Inc. (KOD) | 2025-12-31 | $157.38M | +4.7% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $256.59M | +18.8% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $284.34M | +39.3% |
| Scilex Holding Co (SCLX) | 2025-12-31 | -$207.78M | n/m |
Compare REPL, PROK, PRME, TSHA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗